

E-ISSN: 2664-2301
P-ISSN: 2664-2298
www.gynaecologicalnursing.com
IJOGN 2025; 7(2): 71-74
Received: 05-06-2025
Accepted: 07-07-2025

Geethanjali N
Ph.D. Scholar, Department of Community Health Nursing, Index College of Nursing, Malwanchal University, Indore, Madhya Pradesh, India

Dr. Smriti G Solomon
Principal, Index College of Nursing, Malwanchal University, Indore, Madhya Pradesh, India

Corresponding Author:
Geethanjali N
Ph.D. Scholar, Department of Community Health Nursing, Index College of Nursing, Malwanchal University, Indore, Madhya Pradesh, India

An insight into cervical cancer prevention through the human papillomavirus (HPV) vaccine for the budding generation in India

Geethanjali N and Smriti G Solomon

DOI: https://www.doi.org/10.33545/26642298.2025.v7.i2b.216

Abstract
Cervical cancer is a leading cause of cancer-related fatalities among women in India, primarily resulting from ongoing infections with high-risk types of human papillomavirus (HPV). The persistent nature of these infections underscores the need for a proactive approach to prevention. Vaccination against HPV, particularly in adolescent girls, has demonstrated its effectiveness as a primary prevention method. By preventing the initial infection, the vaccine significantly reduces the risk of cervical cancer, thereby saving countless lives. The vaccine's effectiveness and cost-efficiency make it an ideal solution for preventing cervical cancer. Recent advancements, such as the introduction of locally produced and single-dose vaccines, are expected to enhance accessibility and coverage, ultimately leading to improved health outcomes. However, several challenges persist, including vaccine hesitancy, logistical issues, and a lack of awareness, which must be addressed to ensure the successful implementation of HPV vaccination programs. The Indian government has initiated national initiatives to incorporate HPV vaccination into the Universal Immunisation Programme, with the ultimate goal of achieving widespread protection and making significant progress towards the elimination of cervical cancer.

Keywords: Cervical cancer, HPV vaccine, human papillomavirus, prevention, adolescent girls

Introduction

Cervical Cancer: Disease Overview: Cervical cancer is characterized by the malignant transformation of cervical tissue, primarily resulting from infection with the human papillomavirus (HPV). Notably, types 16 and 18 of HPV are particularly prevalent among women in India and are major contributors to the incidence of this disease. This highlights the critical need for increased awareness and preventive strategies to combat the impact of HPV on women's health in the region [1-2]. The disease is the second leading cause of cancer deaths among women in India, with a significant proportion of the female population at risk [3-4]. Women in low- and middle-income countries, including India, face a higher burden due to limited access to screening and vaccination. Both married and unmarried women are susceptible, and the disease often remains undetected until advanced stages, contributing to high mortality rates [4].

Burden of Cervical Cancer in India

Cervical cancer remains a significant public health issue in India, accounting for 20-23% of the global burden and being the second most common cancer among Indian women [5-7]. Over the last three decades, there has been a significant decline in both the incidence and mortality rates of the disease, with particularly notable reductions observed in states such as Jharkhand and Himachal Pradesh. Nevertheless, the disease remains a substantial contributor to mortality, with a rate of 11.2 per 100, 000 women, which is markedly higher than the global average [8]. The highest occurrence of cases is observed among women in the age group of 55 to 59 years. Unfortunately, a significant number of these cases are diagnosed at later stages, primarily due to inadequate screening measures and a lack of awareness about the condition [9]. Several key risk factors contribute to this issue, including early marriages that may limit individual autonomy, having multiple sexual partners which increases exposure to sexually transmitted infections, and experiencing multiple pregnancies that can

strain a woman's health. Additionally, factors such as poor genital hygiene, which can lead to infections, malnutrition that compromises overall health, and a general lack of awareness about reproductive health all play crucial roles in increasing susceptibility to the disease. Efforts to improve education and access to screening are vital in addressing these risk factors and promoting early detection [10].

Early Prevention Strategies

Screening

India currently faces a significant public health challenge in the form of cervical cancer, largely due to the absence of a comprehensive and coordinated national screening program. Without such a program in place, many women are not receiving timely screenings, resulting in diagnoses that occur at advanced stages of the disease. This delay often leads to increased mortality rates, as late-stage cervical cancer is much more difficult to treat effectively. The lack of organized efforts in cancer prevention and early detection contributes to a growing health crisis that disproportionately affects women across various demographics in the country [11-13]. Screening methodologies such as visual inspection with acetic acid (VIA), visual inspection with Lugol's iodine (VILI), cytology (Pap smear), and HPV DNA testing have demonstrated their effectiveness. Notably, VIA and VILI are particularly advantageous in resource-limited settings due to their simplicity and cost-effectiveness [2, 6-7]. In India, groundbreaking randomized controlled trials have revealed that even a single instance of screening-no matter how brief or limited-can lead to a remarkable reduction in mortality rates. This invaluable insight underscores the profound impact that proactive health measures can have on saving lives [2].

HPV Vaccination

Human papillomavirus (HPV) infection, particularly with types 16 and 18, plays a crucial role in the high incidence of cervical cancer in India, which underscores the importance of targeted health initiatives. By focusing on these specific strains, we can enhance awareness and encourage the implementation of effective vaccination programs. Additionally, promoting regular screening and education around cervical health can empower individuals and communities to take proactive steps in preventing this disease. Ultimately, a comprehensive approach that includes prevention, early detection, and treatment can significantly reduce the burden of cervical cancer in India [3, 12]. India now offers four different HPV vaccines, one of which is an indigenous vaccine that received approval in 2022. This local development is significant as it has the potential to enhance access and increase the uptake of vaccination among the population. Research suggests that extensive HPV vaccination campaigns, especially those utilizing a single-dose schedule, could lead to a remarkable reduction in HPV infection rates by as much as 97%. Moreover, achieving high coverage among girls aged 10 years could significantly diminish the lifetime risk of developing cervical cancer, potentially lowering it by 71% to 78%. This underscores the importance of implementing effective vaccination strategies to protect future generations from this serious health threat [9]. National advisory groups are advocating for a significant increase in the administration of the human papillomavirus (HPV) vaccine, emphasising its crucial role as a primary preventive strategy against HPV-related diseases. These recommendations highlight the importance of expanding vaccination efforts to protect individuals, particularly adolescents, from various cancers linked to HPV, including cervical cancer and others. By enhancing access to and awareness of the HPV vaccine, these organizations aim to improve public health outcomes and reduce the overall incidence of HPV infections [14].

Health System and Policy Initiatives

National initiatives like the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) and Ayushman Bharat are making significant strides in embedding cervical cancer screening and prevention within the primary healthcare framework. These programs emphasize the Visual Inspection with Acetic Acid (VIA) screening method for women aged between 30 and 65, aiming to ensure early detection and timely intervention. Additionally, they advocate for universal health coverage to make these essential services accessible to all [4].

Despite these efforts, several challenges remain. The healthcare infrastructure in many regions is still underdeveloped, leading to inadequate access to screening facilities. Furthermore, there is a notable lack of awareness among the general population regarding the importance of cervical cancer screening. Compounding these issues is the shortage of trained healthcare personnel who are skilled in administering screening procedures and educating women about their health options. Addressing these barriers is crucial for the success of the programs and ultimately improving women's health outcomes [4, 8].

Recommendations for Early Life Prevention

- Promote HPV vaccination for adolescent girls before sexual debut to maximize preventive impact [15]. Implement school- and community-based awareness programs targeting girls, boys, parents, and communities to increase knowledge about cervical cancer and its prevention [3, 5].
- Integrate simple, cost-effective screening methods like VIA/VILI into primary healthcare, especially in high-prevalence areas [2, 4, 6 &16].
- Strengthen health infrastructure and training to ensure effective delivery of vaccination and screening services [4, 8].

Vaccination

1. HPV vaccination is the most effective primary prevention method, capable of preventing over 90% of HPV-attributable cancers [1, 3].
2. Vaccines available in India include bivalent, quadrivalent, nonavalent, and the indigenous CERVAVAC [2, 5].
3. Vaccination is recommended for girls aged 9-14 years, with recent evidence supporting the effectiveness of a single-dose schedule [1-2, 6].

Screening

Screening methods such as visual inspection with acetic acid (VIA), Pap smear, and HPV DNA testing are also effective, especially when combined with vaccination [3-4, 7].

Vaccination Schedule

The recommended vaccination schedule calls for a single

dose administered to girls between the ages of 9 and 19 years. This guideline is in accordance with the most recent directives issued by health authorities and is supported by extensive research demonstrating strong immunogenicity-the ability to provoke a favorable immune response-as well as significant protection against potential health risks. The data collected emphasizes not only the vaccine's safety but also its critical role in safeguarding young women during this pivotal stage of development [1-2, 6].

Implementing catch-up vaccination programs specifically aimed at girls and women up to the age of 20 can significantly amplify the overall effectiveness of public health initiatives. By addressing gaps in vaccination coverage, these programs not only provide essential immunizations but also help protect this demographic from preventable diseases. Engaging communities to promote the importance of these vaccinations can lead to better health outcomes and contribute to societal well-being as a whole [10].

Cost Effectiveness

In India, both the HPV vaccination and the associated screening protocols are considered to be highly cost-effective strategies for combating cervical cancer. The implementation of the HPV vaccine, whether administered as a standalone intervention or in conjunction with regular screening programs, has been shown to significantly lower the incidence and mortality rates associated with cervical cancer. This reduction is achieved while maintaining acceptable incremental cost-effectiveness ratios, making these interventions viable from both a health and economic perspective.

Moreover, the introduction of single-dose vaccination presents an even more efficient approach, particularly in resource-limited settings where healthcare resources are scarce. This single-dose option maximizes the effectiveness of each vaccination administered, offering a practical solution to those in underserved communities [11]. By focusing on these strategies, India can make substantial strides in reducing the burden of HPV-related diseases, ultimately improving public health outcomes [8].

Clinical Trials and Evidence

Indian trials have demonstrated that a single dose of quadrivalent HPV vaccine provides robust and lasting protection against HPV 16 and 18, with similar infection rates to two- and three-dose schedules over seven years [6, 16]. Modelling studies project a 71-78% reduction in lifetime cervical cancer risk with high-coverage vaccination [8].

Challenges and Barriers

Barriers include lack of awareness, vaccine hesitancy, cultural attitudes, logistical issues, and concerns about vaccine duration and safety Limited epidemiological data and prioritization challenges also hinder widespread implementation [2, 4-5].

Government of India Programme

The government has placed a strong emphasis on the ambitious goal of eradicating cervical cancer, setting in motion a comprehensive strategy that includes extensive prevention, screening, and management initiatives. These programs, designed to reach every corner of the community, are implemented under the banner of the National Health Mission, reflecting a commitment to safeguarding women's health and promoting early detection for a brighter, cancer-free future [2-4].

In 2024, the HPV vaccine became a key component of the Universal Immunization Programme, specifically targeting girls between the ages of 9 and 14. This initiative introduced CERVAVAC, an affordable and locally developed vaccine, aimed at enhancing access to critical preventive healthcare. By integrating this innovative vaccine into the national immunization strategy, the program seeks to protect young girls from human papillomavirus, which is known to cause cervical cancer and other related diseases [2, 5].

Conclusion

Cervical cancer continues to cast a daunting shadow over the lives of countless women across India, but the promise of early prevention through the power of HPV vaccination, comprehensive screening, and heightened public awareness offers a beacon of hope that can dramatically lower both the incidence of the disease and the toll it takes on lives. Amplifying the reach of HPV vaccinations-especially by utilizing cost-effective single-dose regimens and homegrown vaccines-while simultaneously establishing robust screening programs, is not just important but essential for realizing the ambitious goal of cervical cancer elimination in India. To confront these challenges head-on, it is imperative to foster public awareness, empower healthcare providers through education, and deploy culturally sensitive campaigns that resonate deeply with diverse communities. Sustained commitment from the government, along with collaborative efforts across multiple sectors, is critical to achieve the WHO's transformative 2030 elimination targets and paving the way for a future free from cancer for the generations yet to come.

Declarations

Funding: None.

Conflict of interest: Not declared.

Ethical approval: Not required.

References

1. Halemani K, J S. Advancements in HPV vaccination for cervical cancer prevention: A comprehensive review. Saudi J Nurs Health Care. 2024;7(5). DOI: 10.36348/sjnhc.2024.v07i05.002
2. Sharma M, Kaur I, Sandhu R, Kaur S. Human papillomavirus vaccine for cervical cancer prevention in India: new improvement and way forward. Int J Community Med Public Health. 2024;11(5). DOI: 10.18203/2394-6040.ijcmph20243322
3. Ramesh S, R S, S S. Human papillomavirus (HPV) vaccination of the girl child: an intervention for primary prevention of cervical cancer in India. Int J Life Sci Pharm Res. 2022;12(6):L165-72. DOI: 10.22376/ijpbs/lpr.2022.12.6.l165-172
4. Deshmukh V, Patil S, Hinge D. The burden and prevention of human papillomavirus (HPV) infections and cervical cancer in India: a literature review. Cureus. 2024;16:e72435. DOI: 10.7759/cureus.72435
5. Dwivedi P, Lahariya A, Pandey S, Sreedevi A, Lohiya A, Lahariya C. Cervical cancer and human papilloma virus (HPV) vaccines: a primer for general physicians.

Prev Med Res Rev. 2024;5(1).
DOI: 10.4103/pmrr.pmrr_16_23
6. Mishra G, Pimple S, Shastri S. Prevention of cervix cancer in India. Oncology. 2016;91(1):1-7. DOI: 10.1159/000447575
7. Singh M, Jha R, Shri N, Bhattacharyya K, Patel P, Dhamnetiya D. Secular trends in incidence and mortality of cervical cancer in India and its states, 1990-2019: data from the Global Burden of Disease 2019 Study. BMC Cancer. 2021;22:732. DOI: 10.1186/s12885-022-09232-w
8. Gupta K, Mandal R, Chatterjee P. Navigating the landscape of cervical cancer in India: epidemiology, prevention, current status, and emerging solutions. J Obstet Gynaecol Res. 2024;50(Suppl 1):S10-S21. DOI: 10.1111/jog.16030
9. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health. 2015;7:405-14.
DOI: 10.2147/IJWH.S50001
10. Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016;37(4):278-85.
DOI: 10.4103/0971-5851.195751
11. Sankaranarayanan R, Bhatla N, Gravitt P, Basu P, Esmy P, Ashrafunnessa K, *et al*. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine. 2008;26(Suppl 12):M43-52.
DOI: 10.1016/j.vaccine.2008.05.005
12. Krishnan S, Madsen E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: implementation science priorities. Oncologist. 2013;18(Suppl 2):13-25.
DOI: 10.1634/theoncologist.18-S2-13
13. Man I, Georges D, De Carvalho T, Saraswati L, Bhandari P, Kataria I, *et al*. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study. Lancet Oncol. 2022;23(11):1422-31.
DOI: 10.1016/S1470-2045(22)00543-5
14. Sankaranarayanan R, Joshi S, Muwonge R, Esmy P, Basu P, Prabhu P, *et al*. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32 Pt A):4783-91.
DOI: 10.1016/j.vaccine.2018.02.087
15. Chauhan A, Prinja S, Srinivasan R, Rai B, Malliga J, Jyani G, *et al*. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020;15(9):e0238291.
DOI: 10.1371/journal.pone.0238291
16. Arora S, Tuffaha H. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India. Asia Pac J Clin Oncol. 2023;20(1):44-53. DOI: 10.1111/ajco.13962

How to Cite This Article
Geethanjali N, Solomon SG. An insight into cervical cancer prevention through the human papillomavirus (HPV) vaccine for the budding generation in India. International Journal of Obstetrics and Gynaecological Nursing. 2025; 7(2): 71-74.